EUVIMEDEUVIMED entdecken
Crossref

Responses of primary human nasal epithelial cells to COVID-19 vaccine candidate

Phissinee Jakaew, Tuksin Jearanaiwitayakul, Panuwat Midoeng, Promsin Masrinoul, Panya Sunintaboon, Sukathida Ubol

Asian Pacific Journal of Allergy and Immunology · 2024

DOI: 10.12932/ap-230523-1623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2024. Verfasst von Phissinee Jakaew und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: COVID-19 Vaccines, Epithelial Cells, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Upper respiratory tract is the primary target of SARS-CoV-2. Therefore, nasal immune responses act as the first line of defense against SARS-CoV-2 infection. OBJECTIVE: We aim to investigate the immune responses of human nasal epithelial cells (HNEpCs) upon stimulation with a COVID-19 vaccine candidate. This candidate named RBD-NPs is composed of SARS-CoV-2 receptor-binding domain (RBD) encapsulated within the N,N,N-trimethyl chitosan nanoparticles (TMC-NPs). METHODS: HNEpCs were stimulated with RBD-NPs, empty NPs, or soluble RBD at various concentrations. After 24 and 48 h of treatment, cells viability and delivery of the immunogens were assessed using XTT assay and flow cytometry. Levels of cytokines and chemokines in the supernatant were quantified with Bio-plex Human Cytokine Assay. Communication between RBD-NPs-stimulated HNEpCs and monocyte-derived dendritic cells (MoDCs) was assessed through differentiation of MoDCs into mature phenotype. RESULTS: RBD-NPs as high as 100 μg exerted no toxicity to HNEpCs and could effectively be delivered to HNEpCs. Treatment of HNEpCs with RBD-NPs strongly activated production of several pro-inflammatory cytokines, chemokines, Th1-related cytokines and the monocytes/macrophages growth factors. Interestingly, soluble mediators secreted from RBD-NPs treated HNEpCs significantly upregulated the expression of maturation markers (CD80, CD83, CD86 and HLA-DR) on the MoDCs. CONCLUSION: This study demonstrated that our COVID-19 vaccine candidate drove HNEpCs into immunologically competent cells that not only exerted anti-viral innate immune responses but also potently induced MoDCs maturation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesEpithelial CellsSARS-CoV-2COVID-19Nasal MucosaHumansDendritic CellsCytokinesChitosanNanoparticlesCells, CulturedSpike Glycoprotein, Coronavirus

Substanzen

COVID-19 VaccinesCytokinesChitosanSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Department of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
  • Department of Clinical Pathology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
  • Center for Vaccine Development, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.
  • Division of Allergy and Clinical Immunology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Chemistry, Faculty of Science, Mahidol University, Salaya, Nakhon Pathom, Thailand.

Zitieren

APA

Jakaew, P., Jearanaiwitayakul, T., Midoeng, P., Masrinoul, P., Sunintaboon, P., & Ubol, S. (2024). Responses of primary human nasal epithelial cells to COVID-19 vaccine candidate. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-230523-1623

Vancouver

Jakaew P, Jearanaiwitayakul T, Midoeng P, Masrinoul P, Sunintaboon P, Ubol S. Responses of primary human nasal epithelial cells to COVID-19 vaccine candidate. Asian Pacific Journal of Allergy and Immunology. 2024. doi:10.12932/ap-230523-1623

BibTeX
@article{Jakaew2024,
  author = {Jakaew, Phissinee and Jearanaiwitayakul, Tuksin and Midoeng, Panuwat and Masrinoul, Promsin and Sunintaboon, Panya and Ubol, Sukathida},
  title = {Responses of primary human nasal epithelial cells to COVID-19 vaccine candidate},
  journal = {Asian Pacific Journal of Allergy and Immunology},
  year = {2024},
  doi = {10.12932/ap-230523-1623}
}
Kostenlos starten →